Navigation Links
Lifeline Biotechnologies' First Warning Systems
Date:7/19/2012

RENO, Nev., July 19, 2012 /PRNewswire/ -- Lifeline Biotechnologies, Inc., (PINKSHEETS: LLBO) announces its primary affiliate and investment, First Warning Systems, Inc., has updated its website with a dynamic video.  The video demonstrates the Company's core technology that identifies breast tumors at the earliest stage.  Many of these tumors could develop into threatening diseases.  The early identification of these tumors is many years ahead of other process capabilities (First Warning's website, firstwarningsystems.com).

Jim Holmes, Lifeline's CEO said, "This video is one of our best summaries of the First Warning Systems' capabilities and explains how and when tumors occur and how doubling times impact their development to a critical stage.  These tumors are breast tissue abnormalities, some of which could develop into threatening diseases such as breast cancers.  We urge all to visit the First Warning website and view this descriptive and informative video." 

About Lifeline Biotechnologies Lifeline Biotechnologies, Inc. (PINKSHEETS: LLBO) founded in 1994 is based in Reno, NV. The Company has licensed its primary affiliate, First Warning Systems, Inc.  The license covers Lifeline's core, patented technology, and conveys the manufacturing and marketing rights to First Warning.  The device and process identifies, at very early stages of development, breast tissue abnormalities some of which are cancerous or pre-cancer.  Patents have been issued based on the results of three clinical trials involving over 650 participants.  The developmental clinical trials confirmed the First Warning Systems' "Proof of Concept," and its capabilities.  www.lbti.com.

About First Warning Systems First Warning Systems (FWS) founded in 2008, based in Reno, NV is an affiliate of Lifeline Biotechnologies, Inc (LLBO).  FWS holds the exclusive development, marketing and manufacturing license to commercialize LLBO's intellectual property for the FWS product line.  The product line is a device and process for early detection of breast tissue abnormalities that provide the opportunity to deal with health risk assessment and management.  Three clinical trials with over 650 participants have achieved superior outcomes when compared to other detection/diagnostic protocols. FWS is planning a final, limited clinical trial followed by a FDA 510(k) device classification submission.  The 510(k) clears the FWS for commercialization.  www.firstwarningsystems.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtaining financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

For more information, contact: Jim Holmes, CEO 775-852-3222 Email: lholmes@lbti.com


'/>"/>
SOURCE Lifeline Biotechnologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Thoratec Schedules First Quarter Conference Call, Webcast
4. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
5. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
8. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
9. Insmed to Host 2012 First Quarter Earnings Conference Call
10. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
11. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... Size, Share, Development, Growth and Demand Forecast to 2022 ... Insulin Pump and Others)" published by P&S Market Research, ... $9,998.3 million in 2015, and it is expected to ... on type, the insulin pump segment is expected to ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment of ... doses of biotin in progressive multiple sclerosis: extension phase results ... Ayman Tourbah , Principal Investigator of the Phase 3 study, ... (EAN) in Copenhagen, Denmark . The oral ... Sunday, 29 May 2016 from 14:45 to 16:15 CEST in ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager ... are unaware of the plight of aphasia. In collaboration with the American Aphasia ... campaign. , The link between stroke and aphasia is relatively unknown, but through ...
(Date:5/27/2016)... ... 27, 2016 , ... With a team of certified experts, ... Aside from its GMP accreditation, Validation Center is also a registered authority of ... and staff. , Validation Center is ISO17025 accredited and only offers its clients ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, ... members and suppliers for its inaugural Member Conference at the Paris Hotel in ... elevating the operational health of America’s healthcare providers. , The conference was highlighted ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... has a significant negative impact on long-term patient survival, reports a team of ... published online this week in the Journal of Thoracic and Cardiovascular Surgery, provide ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey ... , The 550 employees of Sun Health Senior Living (SHSL) may not ... reduces their doctor and prescription copays for the year, while holding the line on ...
Breaking Medicine News(10 mins):